Cobelens F G, Kooij S, Warris-Versteegen A, Visser L G
Division of Infectious Diseases, Tropical Medicine and AIDS. Department of Internal Medicine. Academic Medical Center. Amsterdam, The Netherlands.
J Travel Med. 2000 Jan;7(1):19-24. doi: 10.2310/7060.2000.00005.
Typhoid fever (TF) is a rare disease among travelers to endemic areas, and little is known about its travel-related epidemiology. In addition, efficacy data on TF vaccines in travelers is scanty. During 3 months of 1994/95, six cases of TF were reported in The Netherlands among participants of four package tours to Indonesia provided by the same operator. The present study was designed to describe the epidemiology of TF in these groups, and to assess whether travel groups can be used for studying the efficacy of TF vaccines in travelers.
Questionnaire-based historical cohort study of participants of 4 groups that stayed in the same hotels along their tours (n=156). TF was defined as blood culture-confirmed Salmonella typhi infection. Submitted isolates were typed by antigen and phage typing. Immunization status was considered documented if ascertained by written records.
Among 110 participants (71%), six cases of TF were identified (group specific attack rate AR 5.4%), three of which were from one travel group (AR 12.0%). There were no significant differences by age or sex. Three submitted S. typhi isolates showed three different types, two of which were in the same group. Eighty-three percent of respondents reported documented TF vaccination in the preceding 3 years. All cases occurred in recipients of the oral Ty21a vaccine (AR 10.2%, 95% CI 3.8-20.8%), but differences with nonvaccinees and recipients of the heat-inactivated whole cell or Vi-antigen polysaccharide vaccines were not significant.
Although TF is rare in travelers, infections with different strains of S. typhi can occur in one travel group. Travel groups offer an opportunity for retrospective assessment of vaccine efficacy, provided that equal chance of exposure is largely guaranteed; case ascertainment is maximally specific and similar in the vaccine groups; vaccine status is ascertained accurately; and prior immunity by previous exposures to and use of antibiotics effective against the infection are excluded from, or controlled for in, the analysis.
伤寒热(TF)在前往流行地区的旅行者中是一种罕见疾病,对其旅行相关流行病学知之甚少。此外,旅行者中TF疫苗的疗效数据也很匮乏。1994/95年的3个月期间,荷兰报告了6例TF病例,这些病例来自同一家旅行社组织的4个前往印度尼西亚的旅行团的参与者。本研究旨在描述这些旅行团中TF的流行病学情况,并评估旅行团是否可用于研究TF疫苗对旅行者的疗效。
对4个旅行团中入住相同酒店的参与者(n = 156)进行基于问卷的历史性队列研究。TF定义为血培养确诊的伤寒沙门氏菌感染。提交的分离株通过抗原和噬菌体分型进行鉴定。如果通过书面记录确定免疫状态,则视为有记录。
在110名参与者(71%)中,发现6例TF病例(组特异性发病率AR为5.4%),其中3例来自同一个旅行团(AR为12.0%)。年龄和性别方面无显著差异。提交的3株伤寒沙门氏菌分离株显示出3种不同类型,其中2种在同一组。83%的受访者报告在过去3年中有记录的TF疫苗接种。所有病例均发生在口服Ty21a疫苗的接种者中(AR为10.2%,95%CI为3.8 - 20.8%),但与未接种疫苗者以及热灭活全细胞或Vi抗原多糖疫苗接种者之间的差异不显著。
虽然TF在旅行者中罕见,但同一个旅行团中可能会出现不同菌株的伤寒沙门氏菌感染。旅行团为回顾性评估疫苗疗效提供了机会,前提是在很大程度上保证有平等的暴露机会;病例确诊具有最大特异性且在疫苗组中相似;准确确定疫苗接种状态;并且在分析中排除或控制先前因接触和使用有效对抗该感染的抗生素而产生的免疫力。